Group Says Quarter Of Aussie Biotechs Lack Cash To Last Beyond June
This article was originally published in PharmAsia News
Executive Summary
Australia's budding biotech industry, which includes pharmaceutical and medical device makers, is asking the government for nearly $405 million to help keep it afloat during the current global economy. AusBiotech said about 25 percent of Australian biotechs lack even the cash to operate beyond June. Still others, it said, are faced with choices of whether to stay in Australia where local funds have dried up or take incentives to relocate to other countries. Chairwoman Deborah Rathjen said the request was not a bailout, but "an invigoration of investment." (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.